This activity has expired. Credit is no longer available.
This activity is supported by independent educational grants from Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, Puma Biotechnology, Takeda Oncology.
New Drug Updates in Hematologic Malignancies: CAR T Cells, Targeted Therapeutics, and Other Agents
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Emory University and Winship Cancer Institute
Get an update on the fast-changing world of therapies for hematologic malignancies. With the constantly growing list of new drugs and indications, as well as the introduction of cutting-edge CAR T-cell therapy for the treatment of hematologic malignancies, it’s important that advanced practitioners stay up to date on the latest advances to be able to adequately diagnose, treat, and help patients navigate potential side effects.
These activities, certified for CME/CE/CPE credit, are jointly provided by